MannKind Q4 Revenues Jump 46% to $112M; PDUFA Dates in May, July 2026
MannKind reported Q4 2025 revenues of $112M, up 46% year-over-year, driven by Furoscix net sales of $23M (+91%) and Afrezza net sales of $23M (+25%). Full-year revenues reached $349M (+22%), cash totaled $176M, and FDA PDUFA dates for Afrezza pediatric and Furoscix autoinjector are May 29 and July 26, 2026.
1. Q4 2025 Financial Highlights
MannKind posted Q4 2025 revenues of $112 million, a 46% increase over Q4 2024, led by Furoscix net sales of $23 million (+91% YoY) and Afrezza net sales of $23 million (+25% YoY), while V-Go sales declined 9%. Royalties and collaborations contributed $62 million, up 15% combined.
2. Full Year Results & Balance Sheet
Total revenues for 2025 reached $349 million, a 22% gain from 2024, including $128 million in royalties, $107 million from collaborations and services, $75 million from Afrezza, $23 million from Furoscix and $16 million from V-Go. Cash and investments stood at $176 million as of December 31, 2025.
3. Commercial Portfolio Update
MannKind completed the October 7, 2025 acquisition of scPharmaceuticals, integrating Furoscix injection into its cardiometabolic portfolio. Afrezza received updated dosing guidance, launched in India, and earned inclusion in the 2026 ADA Standards of Care as a routine prandial insulin option.
4. Pipeline and Upcoming Milestones
Key catalysts include FDA PDUFA target dates of May 29, 2026 for Afrezza’s pediatric indication and July 26, 2026 for the Furoscix ReadyFlow autoinjector. Enrollment is underway in the Nintedanib DPI Phase 1b INFLO-1 study with topline data due H2 2026, and a Phase 2 IPF trial begins Q2 2026 alongside MNKD-1501 and Bumetanide DPI preclinical programs.